
In a matched analysis of 15,798 patients, semaglutide reduced the risk of stroke (HR 0.62) compared to empagliflozin, with modest trends favoring semaglutide for MI and death. Dulaglutide showed no significant advantage over empagliflozin. At 3 years, the primary composite outcome occurred in 5.9% (semaglutide) vs. 6.9% (empagliflozin). These findings support semaglutide’s role in cardiovascular risk management in type 2 diabetes.
Like
Save
Share